Supportive treatments

Denosumab for myeloma bone disease: ready for prime time? Dimopoulos MA et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30075-5. doi: 10.1016/S1470-2045(18)30075-5. [Epub ahead of print]. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Raje N et al. Lancet Oncol. 2018 Feb 8. pii: S1470-2045(18)30072-X. doi: 10.1016/S1470-2045(18)30072-X. [Epub ahead of…

Journal, Library, Myeloma Prognosis & Outcomes

General

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print]. Multinucleated giant myeloma cells after failure of daratumumab therapy. Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print]. Defining a set of standardised outcome measures for newly diagnosed patients…

Journal, Library